The objectives of toxicokinetic (TK) studies are to evaluate systemic exposure of the toxicity species to drug and/or metabolite(s) and to relate exposure to dose level and toxicological findings. The tacit assumption is that such exposure can be related to target organ toxicity. Planning a TK program involves early development (often during discovery support) of an appropriate plasma assay, assurance that the studies conform to Good Laboratory Practices, evaluating exposure at steady state, and effective collaboration among toxicologists, kineticists, and other relevant disciplines. The 3 types of TK studies-prospective, concomitant, and retrospective-each have different goals. The various stages of TK program implementation range from those during drug discovery and selection to support of chronic toxicity studies. Exposure is best expressed as the area under the plasma concentration/time curve of drug and/or metabolite(s) and, for highly protein bound drugs, is based on the unbound fraction. Although the objectives of TK programs are generally standard and the Second International Conference on Harmonization has developed TK guidelines, the programs differ among pharmaceutical companies. Some variables in program design and implementation include properties of the drug, formulation used, characteristics of the target species, ability to develop a toxicokinetictoxicodynamic relationship, strategies based on scientific/technical/philosophical considerations, dedicated resources, corporate support, and effectiveness of interdepartmental collaborations.
INTRODUCTION
Among the numerous definitions of &dquo;toxicoki-netics&dquo; (6) , the one that appears in the introduction to the draft tripartite guideline on toxicokinetics released for consultation by the Second International Conference on Harmonization (ICH-2) well defines the scope of the discipline (18): &dquo;Toxicokinetics is defined as the generation of pharmacokinetic data, either as an integral component in the conduct of nonclinical toxicity studies or in specially designed supportive studies, in order to assess systemic exposure. These data may be used in the interpretation of toxicology findings and their relevance to clinical safety issues.&dquo; Toxicokinetics has emerged as an invaluable tool in the conduct and interpretation of drug safety data (11, 13, 15, 16, 28, 48) . However, there are inherent limitations to the use of plasma drug (and/or metabolite) concentrations (15, 19, 25, 28, 32, 41) without consideration that the toxic effect of a drug may better depend on the concentration of relevant drug-derived material at the target site and the sensitivity of the target site. Plasma is an accessible matrix in the toxicology species and humans and is therefore convenient to use in monitoring drug &dquo;exposure.&dquo; However, plasma drug/ metabolite concentrations may not reflect the concentration at the target site. Also, species differ in receptor binding, and a toxic response may not be associated with plasma kinetics. In the ideal world, toxicokinetics should be correlated with some toxicodynamic (TD) endpoint (2) . In general, plasma drug/metabolite concentration comparisons are usually more meaningful than mg/kg dose comparisons ; however, their usefulness as surrogates for drug exposure should be used in context with caseby-case limitations in the interpretation of drug toxicity.
In the pharmaceutical industry, toxicokinetics is being incorporated into drug development pro-grams (3, 22, 40) , and the monitoring of plasma drug levels in toxicology studies has become a relatively routine practice in North America and Europe, but less so in Japan (38. 44) . Regulatory agencies are developing expectations on toxicokinetic (TK) data as an integral part of drug safety assessment studies (20, 29, 36, 39) . In this report, the goals, strategies, design, and implementation of a TK program in support of drug development are described. It should be recognized that TK programs vary among drug companies and should be considered an evolving process based on specific objectives, good science, emerging technology, resources, experience, and interactions between industrial and regulatory institutions. The procedures described herein thus represent those from one pharmaceutical company.
1>LANNING
A TK PROGRAM To plan and implement an effective TK program, specific objectives and goals need to be developed. The primary objectives outlined in the ICH-2 draft guideline (18), i.e., to evaluate systemic exposure and to relate exposure to dose level, represent an international consensus/compromise. The secondary objectives in the ICH-2 guideline are to relate exposure to toxicological findings, to support the choice of species and dosage regimen, to help design subsequent nonclinical toxicity studies, and to assess relevance to clinical safety. The interpretation of TK data based on the preceding objectives has inherent limitations. For example, there may be little or no relationship between exposure and target organ toxicity, so that failure to relate toxicokinetics to a relevant TD endpoint restricts the usefulness of exposure evaluations. Also, toxicologists are limited in the selection of appropriate species for safety evaluation studies; realistically, we are restricted to the rat, mouse, dog, and a few strains of nonhuman primates due to availability, handling experience, and historical databases. In addition, exposure data in animals may or may not be useful in influencing the decision to initiate or to continue studies in human beings.
The objective. strengths and limitations of toxicokinetics in the interpretation of the safety of a new-drug candidate become defined and refined on a case-by-case basis as the properties of the drug are evaluated. With this know-ledge. a focused TK program can be planned. Listed in Table I are some collaborative disciplines in the planning and implementation of a TK program. Formulations research and development (or the equivalent) play a key role in developing a formulation to optimize drug absorption. With the increased tendency to develop ever more potent. and thus usually more lipophilic, drugs, there are increased challenges to assure that. for systemically active drugs, there is at least some relationship between administered dose and exposure. This can become particularly problematic with high doses intended for toxicology studies. Toxicology staff must work closely with other disciplines so as to assure that study designs take into account appropriate TK evaluations. The pivotal role of drug metabolism is to evaluate how best to assess exposure to drug-derived material. Typically, exposure is determined by measuring the plasma concentrations of drug and/or metabolite(s). Based on available metabolism information in the toxicity species and humans, an appropriate bioanalytical technique needs to be developed and validated (46) (Table II ). If the drug produces a major metabolite and both circulate in the body, as with the antihistamine loratadine and its major active metabolite descarboethoxyloratadine, then the assay must include both analytes (27) . For a prodrug, the assay would be focused on the active circulating metabolite(s). If the candidate drug is a racemate, it is important that the assay be stereoselective so that the exposure to the difl'erent enantiomers can be determined (8) . Standard validation criteria include a limit of quantitation that is typically higher for the doses used in toxicology studies compared to the doses used at therapeutic doses in humans. This may necessitate subsequent development of a more sensitive assay for human studies; if this is the case, sufficient cross-validation between the assays is necessary. Because most xenobiotics undergo at least some biotransformation in the body, the question that often arises is what metabolite(s), if any, should be measured in order to appropriately evaluate drug exposure. Species differences in drug metabolism present major challenges in strategy development (4) . Thus, a metabolite may be pharmacologically active or inactive, its toxicity (if any-metabolitespecific toxicity is typically not assessed) may or may not be an extension of its pharmacological activity, and its plasma concentrations, whether relatively low or high, are likely to show species differences (Table II) . Therefore, under what conditions should a metabolite be considered important enough to be included in exposure assessments? It is the author's view that there should be no rigid criteria for such considerations but that the drug sponsor should justify on an individual basis which, if any, metabolite is assayed, whether it be based on percentage of total drug-derived material in the body, species-specific metabolism, relative pharmacological activity, and so forth.
The relevant assay should be developed and validated in a time frame such that it can be utilized in the first investigational new drug-track toxicity studies. The role of the pharmacokineticist is to assure that the toxicology programs incorporate sufficient TK assessment so as to meet program goals and to interpret the data generated. Exposure assessments are best made at steady state rather than after a single dose. TK studies that directly support the toxicology evaluations must be conducted under Good Laboratory Practices (GLP). Because the ultimate exposure comparison is made with humans, the timing of clinical pharmacology studies (Table   I ) should be such that animal/human exposure com- parisons can be generated early enough in the program to help facilitate safety interpretation and to help plan dosage regimens for longer term toxicity (as well as clinical) studies.
IMPLEMENTING A TK PROGRAM: TYPES OF TK STUDIES
TK studies that assess exposure can be divided into 3 categories (Table III) . The general goal of prospective TK studies is to assist the toxicologists in designing their treatment regimens. Although TK evaluations in different species provide data on dose vs exposure to drug and/or metabolite(s), there are practical limitations regarding species selection for chronic studies; thus, the input of TK on species selection is realistically restricted to choosing the dog or the monkey as the nonrodent species. However, early TK studies with different formulations can be critical in selecting the appropriate vehicle for the toxicity tests. The data in Fig laboratories show the profound influence of the effect of formulation on the plasma exposure to a potent highly lipophilic drug, and these findings were used in planning the chronic toxicity study in cynomolgus monkeys. Prospective TK studies will determine at which doses the pharmacokinetics of the drug are linear and whether saturation of absorption or metabolism occurs and can therefore aid in selection of dose magnitude and other aspects of dose regimen (e.g., frequency). The role of prospective toxicokinetics in dose selection for carcinogenicity studies will be discussed later.
Concomitant toxicokinetics refers to those evaluations made during the conduct of the actual toxicity trials, with either study animals or satellite animals. These studies must conform to GLP because they are considered an integral part of the safety evaluation protocols. These data should relate dose to exposure; they may also relate exposure to toxic response if, for example, exposure differences can be integrated with species differences in toxicity, if Fm. 1. -Effect of vehicle on plasma drug concentrations in cynomolgus monkeys following a single high dose of a highly lipophilic drug. Blood samples were serially collected, and each point is the mean of 4 monkeys.
species-specific toxicity may be accompanied by species-specific elevation in exposure, and so forth. Likewise, lack of toxicity at any dose may be associated with saturation in absorption. This is expanded further in this issue (14) . Retrospective (ancillary) (42) TK studies are performed when insufficient exposure data are available from completed toxicology studies. This can occur for drugs whose development has been prolonged ; drug development programs a decade ago typically included negligible TK data, so that it may be necessary to &dquo;revisit&dquo; the conditions of those toxicology studies. An appropriate assay may not have been available at the time the toxicology studies were performed. Often the programs of licensing candidates may not have incorporated sufficient TK data. Also, examination ofTK data from completed studies may uncover an inadequacy that necessitates a repeat study using different sampling times. Should retrospective studies be deemed necessary, it is critical that all attempts be made to duplicate the treatment conditions of the original study and that animals be dosed for a sufficient length of time such that subsequent exposure data can be considered reflective of those in the original study. (TABLE IV) During Drug Drscavery and Selection In recent years, drug metabolism has emerged to play a major role in the discovery and selection of new drugs (12, 24) . The type of data generated will vary depending on the program goals. but often &dquo;bioavailability&dquo; will be provided to complete the following paradigm:
SEVEN STAGES OF DEVELOPMENT AND IMPLEMEIVTATION OF A TK PROGRAM
One of the goals of in vivo pharmacological assessments is to relate dose to effects (e.g., EDSO). Metabolism support can help evaluate whether or not systemic plasma concentrations (bioavailability) can be associated with response. Additionally, preliminary metabolism information, such as extent of metabolism, or presence of major and/or active metabolites, may also be provided. Development and at least &dquo;semivalidation&dquo; of an assay for drug-derived material to assess bioavailability and/or metabolism often forms the basis for helping to explain drug action (or its absence thereof) or duration of action or to aid in the selection of the best drug candidate based on a combination of efficacy and dispositional characteristics. With the proper focus, this early drug metabolism work also represents the genesis of a TK program, insofar that assay development and metabolism information are necessary to implement bioanalytical support. Also, the effects of formulation on bioavailability should be evaluated during the discovery process. Thus, with effective planning, sufficient metabolism and bioanalytical data should be available upon drug selection such that toxicokinetics can be used to help select doses for most investigationa) new drug-track toxicity studies without substantial delays.
r~o.v/c~y A~a~o/~~7 and Kinetic Studies
Because exposure is typically assessed by measuring plasma concentrations of drug and or metabolite(s), some key data are required so that toxicokinetics can be utilileLi m the first IND-tract toBicitB trials (Table 1' ), which are u~ --~-mo studies m a rodent and a nonrodent spc -., discussed. Information on major metabohte(s). the bioana!Bucal approach to assess exposure, and for- mulation effects are often generated during the discovery phase. In vitro metabolism studies in liver preparations from humans and the putative toxicology species can help provide earlier qualitative justification that, based on metabolic profiles, the toxicology species selected are reasonably appropriate (47) . Critical to a valid toxicology study is the assurance from a prospective TK assessment that the (typically) 3 doses to be administered provide 3 different levels of exposure. Likewise, a single-dose pharmacokinetic study using several sampling times can assist in choosing the more limited times for plasma sample collection during the toxicology study. Lack of prospective evaluations with different formulations and/or doses can give rise to the data in Table VI , generated several years ago in our laboratory with a compound evaluated in a 3-mo toxicology study in cynomolgus monkeys. The results showed that the dosage regimens elicited the same exposure with 3 different doses, which helped explain the virtual lack of toxicity at all doses. Thus, the study design did not enable a dose-response evaluation because, at that time, no prospective TK studies were conducted to support development and selection of appropriate dosage regimens.
The design and timing of appropriate TK studies result from project goals, corporate philosophy, available resources, and the level of interdepartmental collaborations and thus vary among institutions (22, 23, 38, 40, 44) . However, it is advisable that sufficient information be generated in a timely fashion such that appropriate exposure data can be generated during the conduct of critical toxicology studies, rather than the less satisfactory approach of conducting retrospective TK studies later in the drug development program.
Toxicokinetic During Pre-IlVD Toxicology Studies
In these first pivotal toxicology studies in a rodent (usually the rat) and nonrodent (dog or monkey) when the drug is typically administered daily at 3 dose levels to male and female animals for 3 mo (sometimes 1 or 6 mo), the goal of concomitant toxicokinetics is to assure that the exposure is dose-related, i.e., exposure increases with dose. This helps to validate the dose regimens selected. The most meaningful exposure parameter is area under the plasma/serum concentration/time curve (AUC), because this defines both absorption and clearance, and is best evaluated at steady state and over the dosage interval (usually 24 hr). Although regulatory agencies focus on AUC (17) , other parameters such as Cmax, C~,;~~~, or even tissue concentrations may, on a case-by-case basis, be deemed more appropriate.
What factors should be addressed to best define exposure based on plasma/serum AUC (Table VII) ? These considerations apply to concomitant TK for all studies, including carcinogenicity evaluations. First, a sufficient number of blood samples are required to estimate the AUC. The blood volume should not be significantly depleted if study animals are used to serially collect blood samples; it is prudent not to collect more than 10% of the blood volume during the AUC sampling interval. For this reason, satellite animals are more often used in rodent studies although, depending on exposure objectives, it is indeed possible with sufficient available pharmacokinetic data in hand to use study animals for TK assessment in rodent toxicity studies (33) . Exposure should certainly be measured at or close to study termination and possibly at earlier stages in the trial to address potential enzyme induction, inhibition, or accumulation. Although it is useful that the bioanalytical method be sufficiently validated prior to study initiation (to assist in dose selection), the program strategy often involves conducting the safety studies as early as possible upon TABLE VL-Exposure during a 3-mo toxicology study in cynomolgus monkeys to a drug candidate for which no prospective TK studies were performed. ATTr&dquo; fA &dquo;&dquo;IA L_B í._J'oo 1.._I_1Bn
a Samples collected at predose (0 hr) and at 1, 3, 6, and 24 hr postdose. Data are means of male and female monkeys (N = 3/dose/sex). drug selection. A &dquo;semivalidated&dquo; assay is often sufficient for the prospective TK studies and may indeed be used for the 3-mo concomitant studies. Full validation to established criteria (37) may occur during or after the study. In such instances, if plasma analyses are delayed, the gamble is taken that the target analyte(s) is stable during this interval.
Obtaining exposure data on the first day of a toxicology study can help in the interpretation of the relationship of dose to exposure. In Table VIII , plasma AUC in rats during a 3-mo study are shown for a drug that was shown to be an enzyme inducer at doses higher than 5 mg/kg/day. Accordingly, exposure to parent drug was the same throughout the study at 5 mg/kg/day but dramatically decreased with time at higher doses. Thus, the less than proportional plasma drug levels at steady state (weeks 5 and 13) between the 5-and 40-mg/kg/day doses was not due to absorption differences but to dosedependent enzyme induction, since the day I exposure values were, in fact, greater than dose-proportional.
For highly protein bound drugs, it is considered more appropriate to express exposure as the free (unbound) fraction, especially for those drugs that demonstrate species differences in the extent of protein binding. It is the author's view that the significance of plasma protein binding may be exaggerated in the interpretation of exposure. After all, protein binding is a dynamic equilibrium process and may not be a contributing factor in species differences in drug distribution. However, if the free (unbound) fraction is to be cited, there should be no arbitrary value (80, 90, 95, 98%) above which a given drug is considered &dquo;highly&dquo; bound. This should be determined and properly justified by the drug sponsor. If protein binding assessments are not complete until a later stage in the drug development program, new calculations may be required to retroactively determine plasma AUCs based on unbound drug.
AD~~IE Studies Initiated Pre-IND and Continued Post-I~'~'D
The ADME (absorption, distribution, metabolism, and excretion) program for a new candidate TABLE VIII. -Exposure during a 3-mo toxicology study in Sprague-Dawley rats to a drug candidate found to undergo dose-dependent enzyme induction. a Samples collected at predose (0 hr) and at l, 3, and hr postdose. drug is generally a continuous process that evolves and becomes more focused as the particular properties of the drug emerge (30) . Some of the ADME studies that can support TK implementation and interpretation have already been discussed, and some may be used retroactively to help interpret the exposure data. For example, the occurrence of (dosedependent) enzyme induction can explain an observation of decreased exposure (or effect) with treatment duration (Table VIII) . Saturation of metabolism or excretion may explain untoward accumulation at higher doses. Target organ toxicity may be related to high tissue radioactivity levels in a separate singleor multiple-dose rat tissue distribution study. Toxicity may be due to a (speciesspecific) toxic metabolite or to the formation of a reactive intermediate. It is critical that an ADME program not only be a packaged checklist aimed at merely satisfying regulatory requirements but that it is also designed and modified in concert with emerging findings in safety evaluation. It should not be overlooked that the principal goal of ADME during development is to support safety and not efficacy.
Identification of the Human Efficacious Dose
The ultimate goal, of course, is the comparison of safety data in animals to that in humans, and early assessment of the human efficacious dose is critical in the initial interpretation of the toxicology findings. Although it is recognized that extrapolation from animals to humans and then back to animals is problematic (7) . the kinetics of the drug in the respective species can sometimes help make species extrapolation somewhat predictive (7, 34, 43) . Human exposure (AUC) is evaluated from a steadystate pharmacokinetics study at the efficacious dose. Only then can the so-called animal human exposure multiple be determined. which is the exposure ratio of animals at a given dose to that in humans. The so-called &dquo;safety margin&dquo; (other terms have been used) refers to the lack of toxicity findings, as follows : safety margin = [(maximum) animal no-observed toxic effect exposure level]
[human exposure level (at the maximum efficacious dose)]. Prior to toxicokinetics, safety margins had often been inappropriately expressed based on animal/human dose levels (mg/kg) rather than exposure levels.
Assessment of animal/human exposure multiples is extremely useful in the planning of doses for the chronic toxicity (including carcinogenicity) studies and requires close collaboration among the clinical pharmacologists, toxicologists, and pharmacokineticists.
Support of Reproductive Toxicology Studies
TK support strategies for reproductive toxicology studies (35) have not received the same attention as those for the other studies, and these programs are generally undergoing development in most pharmaceutical companies. Standard ADME studies include placental transfer, radioactivity distribution in pregnant rats, and transfer to milk of lactating rats. However, in addition, separate studies in species selected for reproductive toxicology tests (if not the same as those for general toxicology studies) may be desirable to define the pharmacokinetics of the drug in these species, so as to enable support of the Segment 2 (including rabbit) and Segment 3 studies.
An argument can be made that demonstration of dose-dependent maternal exposure should be sufficient because with the unique distribution, metabolic and elimination properties of the developing fetoplacental unit, the dam will determine the extent of exposure to the fetus. Thus, the general goal, as with other toxicity studies, should be the demonstration of dose-dependent exposure to relevant drugderived material in the dams.
TK Support for Chronic Toxicity and Carcinogenicity Tests
The issues involved in TK support of chronic (6-12 mo) toxicity studies are similar to those for the pre-IND toxicity evaluations, with the possible exception that, because these studies are generally initiated post-IND, clinical pharmacokinetic data may be available that, together with data from prospective TK studies, will enable development of animal/ human exposure multiples to help assist dose selection. Monitoring the exposure at study termination as well as during the course of these longer term studies may provide information on time-dependent exposure changes; however, changes in metab-olism during chronic toxicity studies may be manifested in toxic changes (e.g., toxic metabolite, change in target organ toxicity) that are so subtle such that there may be no alteration in exposure as determined by plasma drug concentrations (21 ) . TK support of chronic toxicity tests has been subject to controversy and debate, not the least of which is the validity and predictability of the rodent bio. assay itself (1) . Indeed, it has been recommended that the Delaney Clause, enacted in 1958 and, as written, applies solely to food additives and contaminants but not drugs, should be superseded by new legislation that focuses on genotoxic carcinogens so as to be more predictive of human risk, rather than 2-yr rat and mouse studies with diet/ drug mixtures (45) . Coupled with the scientific inadequacy of the rodent bioassay is the concern by some investigators that plasma drug/metabolite concentrations in these tests provide no rational basis for the assessment of human carcinogenic risk (31 ) , while others view toxicokinetics as a tool in data interpretation (2, 10) . Certainly it would be valuable to be able to assess the amount of relevant drug-derived material at the site of toxicity, provided one could identify in advance the (putative) carcinogen (active metabolite?, reactive intermediate ?), identify the target organ, could perform the appropriate assay, and then relate these findings to humans. In the meantime, it appears we must compromise on plasma as an available matrix in both animals and humans and relate dose to exposure (if not exposure to toxicity) using an imperfect animal model.
ICH-2 has recommended that 1 of 5 criteria be used for high dose selection for carcinogenicity studies, one of which is the maximum tolerated dose (MTD), but all 5 of which are considered to be equally acceptable (17) . The other 4 criteria are pharmacodynamic (disturbances in physiology or homeostasis), pharmacokinetic (minimum of 25-fold animal/human exposure multiple), saturation of absorption, and the so-called maximum feasible dose (e.g., 5% of the diet). It is apparent that, with the rat and mouse bioassays still being used and the current international regulatory climate, toxicokinetics must form an integral part of these tests.
Accordingly, as with other toxicology studies, there would appear to be 2 goals in TK support of carcinogenicity assessments: assist in dose selection and evaluate exposure. The opportunity to utilize toxicokinetics prospectively arises with the typical 3-mo pilot studies, which are used in an attempt to establish the MTD. There are numerous variables that impinge on exposure interpretation during these pi-. lot studies (9) . The components of these prospective TK studies are outlined in Table IX . Inherent in the prospective assessment of animal/human exposure multiples is the availability of relevant data from human studies. In our laboratory, these prospective TK evaluations in rats and mice comprise administration of a diet/drug mixture to separate animals at doses that encompass the range used in the 3-mo pilot studies. Study designs can vary (5) , and compromises are necessary regarding treatment duration (with inherent possibility of change in exposure with time). We have treated rodents for 1 mo, groups of animals have been sacrificed every 2 or 3 hr over a 24-hr interval, and plasma drug/metabolite concentrations were measured. Typical plasma concentration/time curves for a particular drug candidate are illustrated in Fig. 2 2. -hlasma drug concentrations in male Sprague-Dawley rats administered a diet/drug mixture for 28 consecutive days. Groups of rats were sacrificed at 2-hr intervals, and each point is the mean of 3 animals. If small sample volumes can be employed in the bioanalytical method, the number of animals can be reduced by withdrawing blood from each rat at 3 selected times over the 24-hr interval. selected, and the issue regarding times to measure exposure during the carcinogenicity studies then arose. It was recognized that single point determinations are insufficient to characterize exposure, yet it would be impractical to collect plasma at 13 times over a 24-hr interval. Similar to other investigators (26), various combinations of 3 time points were used to estimate the AUC(T), based on a recalculation of the AUC (0-24 hr) from 4 time points (assuming the morning concentration was the same at what was designated 0 hr and 24 hr), and based on this critical examination, the best 3 time points were selected (Table X) , which for this drug were the same in both species. The carcinogenicity assessment protocols then included the use of 9 satellite animals/sex/group at sacrifice times of 6, 12, and 18 mo (i.e., 3 animals/sex/dose/sacrifice time); study animals can also be used provided that study integrity is not compromised. The AUCs generated then undergo interpretation considered appropriate for the specific test drug. 
COMMENT
Presented in this overview is just one approach to the design and implementation of a TK program and, for clarity, the focus was on orally administered drugs. There are other specific issues for drugs administered by other routes (e.g., by inhalation). Also, the particular properties of protein/peptide drugs offer unique challenges such that the implementation of a TK program may be different than that for so-called &dquo;conventional&dquo; drugs. Indeed, the differences in TK support programs for biotechnologyderived drugs have been generally ignored. TK programs have the same objectives, i.e., to assess systemic exposure, but the rational implementation of such programs is subject to numerous variables, as listed in Table XI . Given the value and limitations of TK in interpretation of toxicity, and the accessibility of plasma (rather than putative target organs) as an analyzable matrix, compromises are necessary in this inexact science. It is not rational to utilize a checklist approach. The programs must be based on good science, properties of the drug substance and drug product, and institutional culture and resources. Effective collaboration among various disciplines is essential and often affects the ability to implement a focused program. It is critical that TK data be used only as a single tool in overall safety assessments and that attempts be made to relate TK to a relevant TD endpoint. A balance needs to be created between what we would like to do and what we can do, and, because extrapolations from animal data to predicting human risk will always be problematic, TK should be used but not abused as only a part of the inexact science of safety assessment.
